Study guide

10.4 Severe Pyelonephritis, Maternal Pneumonia & Severe Peripartum Infections

C-OBE Obstetric Emergencies Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Maternal Assessment, Risk Stratification & Early Warning Systems

1.1 Pre-Existing Medical, Surgical & Obstetric Comorbidities in Emergency Risk Stratification 1.2 Dynamic Antepartum & Intrapartum Risk Assessment 1.3 Maternal Early Warning Systems (MEWS/MEWT) & Critical Triage Physical Assessment 1.4 Alliance for Innovation on Maternal Health (AIM) Safety Bundles & Emergency Readiness

2 Chapter 2: Obstetric Hemorrhage — Etiology, Assessment & Uterotonics

2.1 Postpartum Hemorrhage Etiology (4 T's) & Quantitative Blood Loss (QBL) 2.2 Uterotonic Pharmacology & Stepwise Administration Protocols 2.3 Tranexamic Acid (TXA) Protocols & Hemorrhage Timing

3 Chapter 3: Obstetric Hemorrhage — Mechanical Interventions, Placental Disorders & Transfusion

3.1 Intrauterine Tamponade Balloons, Compression Sutures & Surgical Hemostasis 3.2 Ectopic Pregnancy, Placenta Previa, Accreta Spectrum (PAS), Abruption & Vasa Previa 3.3 Obstetric DIC, Coagulopathy & Massive Transfusion Protocol (MTP)

4 Chapter 4: Hypertensive Disorders of Pregnancy & Preeclampsia with Severe Features

4.1 Classification & Spectrum of Hypertensive Disorders of Pregnancy 4.2 Preeclampsia with Severe Features: Pathophysiology & End-Organ Damage 4.3 Diagnostic Evaluation, Laboratory Triggers & Fetal Surveillance in Preeclampsia

5 Chapter 5: Hypertensive Crisis, Eclampsia & Magnesium Sulfate Therapy

5.1 Acute Severe Hypertension & First-Line Antihypertensive Protocols 5.2 Eclampsia Recognition, Seizure Management & Airway Protection 5.3 Magnesium Sulfate Neuroprotection/Seizure Prophylaxis Protocols, Monitoring & Toxicity Reversal 5.4 HELLP Syndrome & Hepatic Crisis Management

6 Chapter 6: Maternal Resuscitation, Cardiac Arrest & Perimortem Cesarean

6.1 Maternal ACLS Modifications & Cardiopulmonary Resuscitation Physiology 6.2 Etiologies of Maternal Arrest & Structured Emergency Response 6.3 Perimortem Cesarean Delivery (PMCD / Resuscitative Hysterotomy)

7 Chapter 7: Amniotic Fluid Embolism & Maternal Shock States

7.1 Amniotic Fluid Embolism (AFE): Pathophysiology & Clinical Presentation 7.2 A-OK Protocol, Hemodynamic Support & Critical Care in AFE 7.3 Maternal Shock States: Hemorrhagic, Distributive, Cardiogenic & Obstructive

8 Chapter 8: Acute Intrapartum Delivery Emergencies

8.1 Shoulder Dystocia: Recognition, Timing & Primary HELPERR Sequence 8.2 Advanced Shoulder Dystocia Maneuvers & Neonatal Brachial Plexus Injury Prevention 8.3 Umbilical Cord Prolapse Recognition & Emergent Decompression Protocols

9 Chapter 9: Uterine Inversion, Malpresentation & Obstetric Trauma

9.1 Acute Uterine Inversion: Recognition, Tocolysis & Manual/Surgical Reduction 9.2 Emergency Vaginal Breech Extraction & Head Entrapment Maneuvers 9.3 Maternal Trauma: Primary/Secondary Survey, Placental Abruption & Fetomaternal Hemorrhage

10 Chapter 10: Maternal Sepsis, Intraamniotic Infection & Severe Infections

10.1 Maternal Sepsis: Physiological Criteria, S.O.S. Score & omSOFA 10.2 The Maternal Sepsis Hour-1 Bundle & Fluid/Vasopressor Optimization 10.3 Intraamniotic Infection (Triple I / Chorioamnionitis) & Severe Endometritis 10.4 Severe Pyelonephritis, Maternal Pneumonia & Severe Peripartum Infections

11 Chapter 11: Endocrine, Cardiovascular, Respiratory & Neurologic Emergencies

11.1 Diabetic Ketoacidosis (DKA), Maternal Hypoglycemia & Endocrine Resuscitation in Pregnancy 11.2 Peripartum Cardiomyopathy (PPCM), Acute Heart Failure, Acute Coronary Syndromes & Maternal Arrhythmias 11.3 Status Asthmaticus, Pulmonary Edema & ARDS in Pregnancy 11.4 Status Epilepticus, Acute Stroke & Cerebral Venous Sinus Thrombosis (CVST)

12 Chapter 12: Thromboembolism, Hepatorenal Disorders & Toxicologic Emergencies

12.1 Venous Thromboembolism (DVT/PE) Diagnosis, Treatment & Peripartum Anticoagulation 12.2 Acute Fatty Liver of Pregnancy (AFLP / Swansea Criteria) & Acute Kidney Injury 12.3 Peripartum Substance Overdose, Opioid Toxicity & Naloxone Administration

13 Chapter 13: Obstetric Anesthesia Emergencies & Critical Complications

13.1 High Spinal / Total Spinal Anesthesia & Aspiration Pneumonitis 13.2 Local Anesthetic Systemic Toxicity (LAST) & 20% Lipid Emulsion Rescue Protocol 13.3 Post-Dural Puncture Headache (PDPH), Epidural Hematoma & Abscess 13.4 Malignant Hyperthermia in Obstetric Anesthesia & Dantrolene Protocol

14 Chapter 14: Professional Practice, Team Communication, Debriefing & Health Equity

14.1 Crisis Resource Management (CRM), TeamSTEPPS & Structured Communication 14.2 Multidisciplinary Emergency Debriefing, Morbidity & Mortality, and Systems Learning 14.3 Perinatal Racial/Ethnic Disparities, Implicit Bias Mitigation & Respectful Maternity Care 14.4 Legal, Ethical, Documentation & EMTALA Standards in Obstetric Emergencies

10.4 Severe Pyelonephritis, Maternal Pneumonia & Severe Peripartum Infections

Key Takeaways Explain This Topic AI

Acute pyelonephritis complicates 1% to 2% of pregnancies due to progesterone-mediated ureteral smooth muscle relaxation, mechanical compression by the dextrorotated gravid uterus, and physiological hydronephrosis (right > left in >85% of cases), carrying a 2% to 8% risk of endotoxin-mediated Acute Respiratory Distress Syndrome (ARDS), uroseptic shock, and preterm labor.

Inpatient management of antepartum pyelonephritis requires IV hydration, blood/urine cultures, and parenteral beta-lactams (e.g., Ceftriaxone 1 g IV every 24 hours, or Ampicillin plus Gentamicin) until afebrile for 48 hours, followed by culture-directed oral therapy for 10–14 days and continuous daily suppressive antibiotic prophylaxis (Nitrofurantoin 100 mg PO daily or Cephalexin 250–500 mg PO daily) for the remainder of pregnancy.

Severe maternal pneumonia and viral pneumonitis (Influenza, COVID-19, Varicella) rapidly cause maternal hypoxemic respiratory failure due to pregnancy-induced reductions in functional residual capacity (FRC decreased 20–30%) and elevated oxygen consumption; empirical antiviral therapy (Oseltamivir 75–150 mg PO BID for influenza; IV Acyclovir 10–15 mg/kg Q8H for varicella) must be initiated immediately without awaiting lab confirmation, maintaining target maternal SpO2 ≥95% (PaO2 ≥70 mmHg).

Necrotizing soft tissue infection (necrotizing fasciitis) of episiotomy or cesarean incisions is a surgical emergency characterized by pain out of proportion to exam findings, skin bullae, dusky violaceous discoloration, subcutaneous crepitus, and systemic toxic shock, requiring emergent radical surgical debridement of non-viable tissue to bleeding borders and triple-drug antimicrobial coverage including IV clindamycin for toxin suppression.

Last updated: August 2026

Severe Pyelonephritis, Maternal Pneumonia & Severe Peripartum Infections

Severe extrauterine and surgical infections during pregnancy and the puerperium pose acute risks of multi-organ dysfunction, septic shock, and maternal-fetal demise. The anatomical, mechanical, and immunomodulatory alterations of pregnancy unique to the urinary tract, pulmonary parenchymal tree, and pelvic soft tissues dramatically accelerate infectious spread and increase susceptibility to life-threatening complications such as endotoxin-mediated Acute Respiratory Distress Syndrome (ARDS) and necrotizing fasciitis.

1. Acute Pyelonephritis in Pregnancy: Pathophysiology & Urosepsis

Acute pyelonephritis occurs in 1% to 2% of all pregnant women, representing the most common non-obstetric antepartum cause of maternal septic shock and ARDS.

Anatomical & Hormonal Predisposing Factors

Progesterone-Induced Hydroureter: Circulating progesterone exerts a potent inhibitory effect on ureteral smooth muscle tone and peristalsis, resulting in ureteral dilation (hydroureter) and stasis starting as early as the first trimester.

Mechanical Compression & Dextrorotation: By the second trimester, the enlarging gravid uterus compresses the ureters at the pelvic brim as they cross the iliac vessels. Because the uterus is physiologically dextrorotated by the sigmoid colon, compression of the right ureter and right ovarian venous plexus is far more pronounced, causing right-sided hydronephrosis in >85% of cases .

Physiological Glucosuria & Aminoaciduria: Increased GFR combined with altered tubular reabsorption provides an ideal rich culture medium for bacterial proliferation. +---------------------------------------------------------------------------------------------------+

  • | MICROBIOLOGY & COMPLICATIONS OF ANTEPARTUM PYELONEPHRITIS |
  • | |
  • | • PRIMARY UROPATHOGENS: |
  • | - Escherichia coli (75% to 85% of cases; primary producer of lipid A endotoxin). |
  • | - Klebsiella pneumoniae, Proteus mirabilis, Enterobacter species (10% to 15%). |
  • | - Group B Streptococcus (Streptococcus agalactiae), Enterococcus faecalis (3% to 5%). |
  • | |
  • | • LIFE-THREATENING COMPLICATIONS: |
  • | 1. Endotoxin-Mediated Alveolar Damage & ARDS (2% to 8% of hospitalized cases): |
  • | - Lipopolysaccharide (LPS) endotoxin release damages alveolar-capillary endothelial cells, |
  • | precipitating diffuse capillary leak, severe hypoxemia, and pulmonary edema. |
  • | 2. Uroseptic Shock: Systemic vasodilation, profound hypotension, and multi-organ failure. |
  • | 3. Transient Acute Kidney Injury (AKI): Endotoxin-mediated intrarenal vasoconstriction and GFR |
  • | decline (creatinine > 1.0 mg/dL). |
  • | 4. Preterm Labor & Delivery: Endotoxins stimulate uterine prostaglandin (PGF2a) release. |
  • +---------------------------------------------------------------------------------------------------+
  • Inpatient Clinical Management Protocol

Mandatory Hospital Admission: All pregnant women with suspected acute pyelonephritis must be admitted for inpatient parenteral therapy.

Diagnostic Workup: Obtain CBC with differential, serum creatinine, BUN, electrolytes, venous lactic acid, catheterized urinalysis with urine culture/sensitivity, and two sets of blood cultures (bacteremia occurs in 15% to 20% of antepartum pyelonephritis).

Intravenous Hydration: Cautious crystalloid hydration to restore urine output (target 30–50 mL/h) while monitoring closely for signs of fluid overload.

Parenteral Antimicrobial Therapy: +---------------------------------------------------------------------------------------------------+

  • | ANTIMICROBIAL REGIMENS FOR ANTEPARTUM PYELONEPHRITIS |
  • | |
  • | • FIRST-LINE EMPIRIC REGIMEN (Low Risk for Resistant Pathogens): |
  • | - **Ceftriaxone 1 g IV every 24 hours** (or Cefepime 1–2 g IV every 12 hours). |
  • | - Alternative: Ampicillin 1–2 g IV every 6 hours PLUS Gentamicin 5 mg/kg IV every 24 hours. |
  • | |
  • | • SEVERE SEPTIC SHOCK OR HIGH RISK FOR ESBL (Extended-Spectrum Beta-Lactamase): |
  • | - **Meropenem 1 g IV every 8 hours** OR Ertapenem 1 g IV every 24 hours. |
  • | |
  • | • TRANSITION & DURATION: |
  • | - Step down to culture-directed oral antibiotics after the patient is **afebrile for 48 hours**|
  • | with resolving flank pain (e.g., Cephalexin 500 mg Q6H, Cefpodoxime 200 mg Q12H, or |
  • | Amoxicillin-Clavulanate 875/125 mg Q12H). |
  • | - Complete a total antimicrobial treatment duration of **10 to 14 days**. |
  • | |
  • | • MANDATORY DAILY SUPPRESSIVE PROPHYLAXIS: |
  • | - Following completion of the 14-day treatment course, initiate continuous daily suppressive |
  • | antibiotic prophylaxis for the remainder of pregnancy and up to 6 weeks postpartum: |
  • | - **Nitrofurantoin (Macrodantin) 100 mg PO daily at bedtime**, OR |
  • | - **Cephalexin 250–500 mg PO daily at bedtime**. |
  • | - Rationale: Without daily suppressive therapy, the recurrence rate of pyelonephritis during |
  • | the same pregnancy exceeds 20% to 30%. |
  • +---------------------------------------------------------------------------------------------------+
  • 2. Maternal Pneumonia & Severe Viral Pneumonitis

Pneumonia during pregnancy carries substantial maternal morbidity and mortality. Pregnancy alters respiratory physiology in ways that leave the mother uniquely vulnerable to rapid hypoxemic decompensation:

Decreased Functional Residual Capacity (FRC): Diaphragmatic elevation (up to 4 cm) by the gravid uterus decreases FRC by 20% to 30%, severely diminishing the maternal oxygen reserve.

Increased Oxygen Consumption (VO2): Maternal metabolic demands and fetal-placental requirements increase baseline oxygen consumption by 20% to 30%.

Physiological Shift: The combination of reduced FRC and increased VO2 causes the pregnant patient to desaturate rapidly during periods of hypoventilation or ventilation-perfusion mismatch.

Clinical Management of Community-Acquired & Viral Pneumonias +---------------------------------------------------------------------------------------------------+

  • | ETIOLOGY & TARGETED THERAPY FOR MATERNAL PNEUMONIA |
  • | |
  • | 1. COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (CAP): |
  • | • Pathogens: Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, |
  • | Chlamydia pneumoniae, Legionella pneumophila. |
  • | • Regimen: **Ceftriaxone 1–2 g IV every 24 hours PLUS Azithromycin 500 mg IV/PO daily** |
  • | (or Ampicillin-Sulbactam 1.5–3 g IV Q6H + Azithromycin). |
  • | |
  • | 2. INFLUENZA PNEUMONIA (Severe Maternal Mortality Risk): |
  • | • Pathophysiology: Rapidly progressive primary viral pneumonitis and secondary bacterial |
  • | superinfection (S. aureus, MRSA). |
  • | • Immediate Treatment: **Oseltamivir (Tamiflu) 75 mg PO twice daily for 5 days** |
  • | (increase to 150 mg PO BID in critically ill / intubated patients). |
  • | • CRITICAL RULE: Initiate empiric oseltamivir IMMEDIATELY upon clinical suspicion; do NOT |
  • | delay treatment while awaiting diagnostic viral PCR swabs! Treatment is most effective when |
  • | started within 48 hours but provides clear survival benefits even when started later. |
  • | |
  • | 3. COVID-19 VIRAL PNEUMONIA & ARDS: |
  • | • Management in Hypoxemic Pregnancy: |
  • | - Remdesivir 200 mg IV loading dose, then 100 mg IV daily for 5 days (safe in pregnancy). |
  • | - Dexamethasone 6 mg IV daily for up to 10 days (if requiring supplemental oxygen). |
  • | * Note: If fetal lung maturity is indicated (<34 weeks), use standard betamethasone |
  • | 12 mg IM Q24H x 2 doses, then resume maternal dexamethasone 6 mg daily. |
  • | - Therapeutic or Prophylactic Anticoagulation (LMWH) due to severe thromboembolism risk. |
  • | - Tocilizumab (IL-6 inhibitor) or Baricitinib (JAK inhibitor) for progressive failure. |
  • | |
  • | 4. VARICELLA PNEUMONIA: |
  • | • Maternal mortality historically 10% to 35% in pregnant women with varicella rash. |
  • | • Treatment: **Acyclovir 10–15 mg/kg IV every 8 hours for 7 to 10 days** started immediately. |
  • +---------------------------------------------------------------------------------------------------+
  • Maternal-Fetal Oxygenation Targets & Ventilator Adjustments

Target Maternal Oxygenation: Maintain maternal SpO2 ≥ 95% (corresponding to an arterial PaO2 ≥ 70 mmHg ) at all times. A maternal PaO2 <60 mmHg results in a precipitous drop along the maternal oxyhemoglobin dissociation curve, compromising the placental oxygen diffusion gradient and inducing severe fetal hypoxia and acidosis.

Ventilator Settings in Pregnancy:

Target PaCO2: 28 to 32 mmHg (to match the physiological compensated respiratory alkalosis of pregnancy). Avoid PaCO2 >35 mmHg (which creates respiratory acidosis) and avoid aggressive hyperventilation with PaCO2 <25 mmHg (which causes uterine artery vasoconstriction and impairs fetal oxygen unloading via the Bohr effect).

Low Tidal Volume Strategy: 6 mL/kg predicted body weight with plateau pressure <30 cmH2O to prevent barotrauma.

Prone Positioning: Safe in second and third trimester pregnancy when properly padded to avoid direct abdominal compression.

3. Necrotizing Soft Tissue Infections of Episiotomy & Cesarean Wounds

Necrotizing fasciitis of the perineum (Fournier's gangrene) following episiotomy or of the anterior abdominal wall following cesarean section is an uncommon but rapidly lethal surgical emergency with maternal mortality approaching 20% to 50% without prompt surgical debridement. +---------------------------------------------------------------------------------------------------+

  • | PERIPARTUM NECROTIZING FASCIITIS CLINICAL PROTOCOL |
  • | |
  • | • PATHOPHYSIOLOGY & CLASSIFICATION: |
  • | - **Type I (Polymicrobial - 70% to 80%):** Synergistic mixture of obligate anaerobes |
  • | (Bacteroides, Peptostreptococcus) and facultative aerobes (E. coli, Klebsiella, Enterococcus).|
  • | - **Type II (Monomicrobial - 20% to 30%):** Group A Streptococcus (Streptococcus pyogenes) or |
  • | Community-Acquired MRSA. Characterized by rapid, virulent tissue destruction and toxic shock. |
  • | |
  • | • CLINICAL HARBINGERS & PRESENTATION: |
  • | 1. **Pain Out of Proportion to Exam:** Agonizing perineal or incisional pain that exceeds |
  • | visible superficial findings. |
  • | 2. **Skin Changes:** Initial erythema and tense edema progressing rapidly to dusky, violaceous,|
  • | gray-bronze discoloration with fluid-filled bullae and frank skin breakdown. |
  • | 3. **Subcutaneous Crepitus & Gas:** Palpable subcutaneous crackling or soft tissue gas on |
  • | imaging (CT or X-ray). |
  • | 4. **Cutaneous Hypesthesia / Anesthesia:** Loss of sensation over the affected area due to |
  • | thrombosis of nutrient vessels and necrosis of dermal nerve endings (ominous sign). |
  • | 5. **Systemic Toxic Shock:** High fever, tachycardia, hypotension, leukocytosis, and altered |
  • | mental status. |
  • | |
  • | • EMERGENCY SURGICAL & MEDICAL MANAGEMENT: |
  • | 1. **EMERGENCY RADICAL SURGICAL DEBRIDEMENT (The Definitive Life-Saving Intervention):** |
  • | - Immediate transfer to the operating room; do NOT delay surgery for imaging or antibiotics!|
  • | - Wide, aggressive excision of all necrotic skin, subcutaneous fat, and fascial layers |
  • | back to healthy, bleeding tissue ('dishwater pus' and lack of fascial resistance noted). |
  • | - Planned mandatory re-exploration and repeat debridement in the OR in **24 to 48 hours**. |
  • | 2. **TRIPLE-DRUG BROAD-SPECTRUM ANTIMICROBIAL REGIMEN:** |
  • | - **Meropenem 1 g IV every 8 hours** (or Piperacillin-Tazobactam 4.5 g IV Q6H) |
  • | PLUS **Vancomycin 15–20 mg/kg IV every 8–12 hours** |
  • | PLUS **Clindamycin 900 mg IV every 8 hours**. |
  • | - Role of Clindamycin: Acts on bacterial 50S ribosomal subunit to suppress synthesis of |
  • | Streptococcal M-protein, Streptolysin O, and Staphylococcal Toxic Shock Syndrome Toxin-1 |
  • | (Eagle effect / antitoxin activity). |
  • +---------------------------------------------------------------------------------------------------+

Loading diagram... Severe Extrauterine & Soft Tissue Infections Emergency Pathway